Evommune EVMN 深 沪
等待开盘 09-17 09:30:00 美东时间
9.37
-0.620
-6.21%
华盛通- 最 高9.99
- 今 开9.98
- 成交量 56.89万股
- 最 低 9.3006
- 昨 收 9.99
- 总市值 3.40亿
- 52周最高 33.20
- 市盈率 静 --
- 换手率 1.57%
- 52周最低 9.3006
- 委 比 -42.86%
- 总股本 3629.21万
- 历史最高 33.20
- 量 比 0.48
- 振 幅 6.90%
- 历史最低 9.3006
- 每 手 1
- 风险率 5.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $21
RBC Capital analyst Brian Abrahams maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $29 to $21.
09-09 21:33
Evommune Halts Atopic Dermatitis Program Following Trial Failure
On Tuesday, clinical-stage biotechnology company Evommune Inc. (NYSE:EVMN) announced topline results from its dose-ranging Phase 2b trial assessing oral EVO756 for moderate-to-severe atopic dermatitis. Phase 2b Clinical Trial Findings The study evaluated the efficacy and safety profile of oral EVO75...
09-09 19:40
HC Wainwright & Co. Reiterates Neutral on Evommuneto Neutral
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Evommune (NYSE:EVMN) from Neutral to Neutral.
09-09 18:32
美股大行评级 | 潜在涨幅1849.95%！Ascendiant Capital上调IGC Pharma目标价至6美元，维持"买入"评级；迪克体育、财捷遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.5美元升至6美元；Ascendiant Capital：维持Quantum Computing"买入"评级，目标价从30美元升至32美元
08-27 08:37
Needham Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $28
Needham analyst Serge Belanger initiates coverage on Evommune (NYSE:EVMN) with a Buy rating and announces Price Target of $28.
08-26 18:47
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $29
RBC Capital analyst Brian Abrahams maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $30 to $29.
08-08 03:21
